Logo

Kite's KTE-X19 Receives the US FDA's Priority Review for Relapsed or Refractory Mantle Cell Lymphoma

Share this

Kite's KTE-X19 Receives the US FDA's Priority Review for Relapsed or Refractory Mantle Cell Lymphoma

Shots:

  • The US FDA has accepted BLA and granted PR designation to Kite’s KTE-X19 for the treatment of patients with r/r MCL
  • The BLA is based on P-II ZUMA-2 study assessing KTE-X19 in 74 patients aged ≥18yrs. with r/r MCL following up to prior 5L therapies including an anthracycline- bendamustine-containing CT- anti-CD20 mAb and the BTK inhibitors (ibrutinib/acalabrutinib)
  • KTE-X19 is an investigational- autologous- anti-CD19 CAR T cell therapy- currently being evaluated in P-I/II study for ALL- MCL & CLL and has received FDA’s BT and EMA’s PRIME designation for r/r MCL with its anticipated PDUFA date as Aug 10- 2020

Click here ­to­ read full press release/ article | Ref: Gilead | Image: Kite Pharma


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions